Based on abnormal signaling pathways and their downstream cellular dysfunctions in AD, significant biomarkers were selected as drug targets, i.e., IL-1β, GATA3, Akt, and NF-κB, from these abnormal signaling pathways and their downstream cellular dysfunctions in AD. The gene discussed is NFKB1; the disease is Alzheimer disease.